Rakhi Kumar - Sep 8, 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
Chief Accounting Officer
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Rakhi Kumar
Stock symbol
ROIV
Transactions as of
Sep 8, 2023
Transactions value $
-$566,295
Form type
4
Date filed
9/12/2023, 09:30 PM
Previous filing
Sep 7, 2023
Next filing
Sep 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $644K +99.4K +50.19% $6.48 297K Sep 8, 2023 Direct
transaction ROIV Common Shares Sale -$1.21M -99.4K -33.42% $12.18 198K Sep 8, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -99.4K -100% $0.00* 0 Sep 8, 2023 Common Shares 99.4K $6.48 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
F2 Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested